A real-world data (RWD) study published in JAMA Oncology finds that administering immunotherapy to patients with advanced non-small cell lung cancer (NSCLC) is appropriate. The study, which followed 1091 patients at Penn Medicine's Abramson Cancer Center, found that patients whose cancer hasn't progressed after two years of immunotherapy did not gain any clinical benefits by prolonging treatment past a 2-year period.
According to lead author Lova Sun, MD, “We hope this data provides reassurance that stopping treatment at two years is a valid treatment strategy that does not seem to compromise overall survival. In the absence of definitive prospective data about the duration of therapy – which will take years to accumulate – our goal was to use real-world observational data to provide guidance on this important clinical question.”
To read more, click here.
(Source: Penn Medicine News, June 4th, 2023)
